Efficiency of transcutaneous electrical nerve stimulation in the treatment of central and peripheral disorders of the nervous system

Analgesic and recovery effect of transcutaneous electrical nerve stimulation in treatment of central and peripheral neurological disorders

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN47534508

Enrollment

300

Registered

2024-12-02

Start date

2023-01-04

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pathology of the peripheral or central nervous system Nervous System Diseases

Interventions

The treatment group receives effective transcutaneous electrical nerve stimulation. Each procedure lasts 20-30 minutes. The procedures are carried out 15 times every other day. In the control group,

Eligibility

Sex/Gender

All

Age

25 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. European 2. Adults aged from 25 to 60 years old 3. Neurological disorder is older than 3 months but less than 2 years 4. The severity of pain by visual analogue scale (VAS) is 5 scores and higher 5. Changes in the neurophysiological examination of the nervous system: electromyography, electroencephalography, evoked potentials 6. Signed voluntary informed consent to participate in this study

Exclusion criteria

Exclusion criteria: 1. Presence of allergic reactions to any of the drugs used 2. Severe cognitive disorders 3. Epilepsy 4. Rheumatoid diseases 5. Atherosclerotic peripheral arterial disease of the lower extremities 6. Muscular dystrophies of the lower extremities 7. Diabetes mellitus 8. Pregnancy 9. Undergoing physiotherapy or acupuncture treatment

Design outcomes

Primary

Measure	Time frame
Current primary outcomes as of 06/05/2026: Before treatment, a week after treatment, after 2 months and after 4 months of observation: 1. Pain assessment by visual analogue scale and McGill Pain Questionnaire 2. Assessment of impaired sensation: temperature, tactile and vibratory sensation by a 5-point scale 3. Assessment of neurogenic claudication by Zurich Claudication Questionnaire (ZCQ) 4. Step activity monitoring by a pedometer 5. Motor deficit by 5-point scale 6. Electroneuromyography (ENMG): 6.1. Amplitude of Compound Muscle Action Potential (CMAP): 6.2. Terminal Latency 6.3. Conduction Velocity 6.4. Amplitude of Evoked Potential of Sural Nerves 6.5. F-wave and A-wave Abnormalities 7. MRI will measure the narrowing of the spinal canal at the L4-S1 level before and after decompression surgery and at the end of the follow-up period. 8. Postural control examination and posturography Previous primary outcomes: Before treatment, a week after treatment, after 2 months and after 4 months of observation: 1. Pain assessment by visual analogue scale and McGill Pain Questionnaire 2. Assessment of impaired sensation: temperature, tactile and vibratory sensation by a 5-point scale 3. Assessment of neurogenic claudication by Zurich Claudication Questionnaire (ZCQ) 4. Step activity monitoring by a pedometer 5. Motor deficit by 5-point scale 6. Electroneuromyography (ENMG): 6.1. Amplitude of Compound Muscle Action Potential (CMAP): 6.2. Terminal Latency 6.3. Conduction Velocity 6.4. Amplitude of Evoked Potential of Sural Nerves 6.5. F-wave and A-wave Abnormalities 7. MRI will measure the narrowing of the spinal canal at the L4-S1 level before and after decompression surgery and at the end of the follow-up period.	—

Measure

Time frame

Current primary outcomes as of 06/05/2026: Before treatment, a week after treatment, after 2 months and after 4 months of observation: 1. Pain assessment by visual analogue scale and McGill Pain Questionnaire 2. Assessment of impaired sensation: temperature, tactile and vibratory sensation by a 5-point scale 3. Assessment of neurogenic claudication by Zurich Claudication Questionnaire (ZCQ) 4. Step activity monitoring by a pedometer 5. Motor deficit by 5-point scale 6. Electroneuromyography (ENMG): 6.1. Amplitude of Compound Muscle Action Potential (CMAP): 6.2. Terminal Latency 6.3. Conduction Velocity 6.4. Amplitude of Evoked Potential of Sural Nerves 6.5. F-wave and A-wave Abnormalities 7. MRI will measure the narrowing of the spinal canal at the L4-S1 level before and after decompression surgery and at the end of the follow-up period. 8. Postural control examination and posturography Previous primary outcomes: Before treatment, a week after treatment, after 2 months and after 4 months of observation: 1. Pain assessment by visual analogue scale and McGill Pain Questionnaire 2. Assessment of impaired sensation: temperature, tactile and vibratory sensation by a 5-point scale 3. Assessment of neurogenic claudication by Zurich Claudication Questionnaire (ZCQ) 4. Step activity monitoring by a pedometer 5. Motor deficit by 5-point scale 6. Electroneuromyography (ENMG): 6.1. Amplitude of Compound Muscle Action Potential (CMAP): 6.2. Terminal Latency 6.3. Conduction Velocity 6.4. Amplitude of Evoked Potential of Sural Nerves 6.5. F-wave and A-wave Abnormalities 7. MRI will measure the narrowing of the spinal canal at the L4-S1 level before and after decompression surgery and at the end of the follow-up period.

—

Secondary

Measure	Time frame
Before treatment, a week after treatment, after 2 months and 4 months of observation: 1. Quality of life by SF-36 questionnaire 2. Quality of enjoyment by Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) 3. Assessment of sexuality disorders by the Sexual Function Evaluation Questionnaire (SFEQ)	—

Countries

Russian Federation

Contacts

Public ContactMustafa Al-Zamil

alzamil@mail.ru+7 89262893810

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Aug 9, 2026